Cosmos Holdings Inc (NASDAQ: COSM) is an enormous short squeeze that is rocketing up the charts while the overall market are weak. On Monday COSM was up over 10% at one point but closed at $0.57 up 6.5% while the Nasdaq lost just under 500 points on the day. COSM is quickly going viral and is currently among the top most trending stocks on Stocktwits, the top most mentioned stock on the sub reddit Short Squeeze, and there are dozens of Youtube channels reporting on it and private discord groups buying COSM from all over the world.
While COSM was shorted into oblivion the Company is strong recently reporting $12 million in revenues in Q3 as well as rapid growth through acquisition with 3 major acquisitions currently on the table. COSM is led by able CEO Grigorios Siokas, a high level pharmaceutical executive Mr. Siokas is a major shareholder in Ippokratis Pharmaceuticals, Thrakis Pharmaceuticals, Thessalias Pharmaceuticals, and ZED Pharma SA. Since 2019, Mr. Siokas has invested over $10.6M at an average price of $5.25 of his personal wealth into Cosmos. More recently Mr. Siokas acquired another 1,131,098 shares on Friday adding to the 481,079 shares acquired Thursday adding to his previous buy of 800,000 shares at $0.62 earlier last week. This comes after Mr. Siokas acquired 12.5 million shares price at $0.12 as part of a securities purchase agreement in October.
COSM Tuesday Update: COSM is coming back moving back over $0.50 in late day trading Tuesday. The stock saw a significant drop this morning after the Company filed an 8k on Monday that stated the board had approved several matters including: “(6) to authorize the Board of Directors to amend the Articles of Incorporation to effect a reverse stock split of the Company’s outstanding common stock at their discretion.” This does not mean COSM is going to do a reverse split. It means the BOD has approved it so they can affect a RS at their discretion if they need to. It’s certainly in managements best interest not to do a reverse stock split. However, the Nasdaq listing is more important so they will use it if they have to. We gave the heads up on COSM when the stock was below $0.10 per share at the beginning of November. We will be updating on COSM as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below.
Cosmos Holdings Inc
(NASDAQ: COSM) is an international healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. The group in engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation”. Cosmos Holdings Inc. is operating in the pharmaceutical sector as well, through the provision of a broad line of branded generics and OTC medications. In addition, the group is involved in the healthcare distribution sector through its subsidiaries in EU and UK serving retail pharmacies and wholesale distributors. Cosmos Holdings Inc. is strategically focusing on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Management is focused on Branded Pharmaceuticals, Generic Pharmaceuticals, Health Products & Food Supplements, Research & Development, and Local & Direct to Pharmacy Wholesale. Check out the Company’s latest presentation here.
In Q3, 2022 Cosmos reported $12 million in revenues and made a number of important advancements including raising $7.5 million via a public offering, entered into an agreement to restructure its warrents to avoid dilution, announced an agreement to market and distribute Nickelodeon’s SpongeBob and PAW Patrol kids’ vitamins in Greece and Cyprus, aiming to reach out 11,000 pharmacies and 120 wholesalers in Greece and 780 pharmacies in Cyprus and much more.
COSM Rapid Growth Though Acquisition:
Cosmos has a plan for rapid growth through acquisition; currently the Company is evaluating acquisition targets that allows it to expand its distribution reach and/or vertically integrate into its supply chain of the products. COSM is also actively pursuing accretive acquisitions that offer long-term revenue growth, margin expansion through synergies, and the ability to maintain a flexible capital structure.
COSM acquisitions currently on the table:
- Entered into an LOI to acquire ZipDoctor Inc., a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and therapists.
- Entered into an agreement to acquire LIFE NLB, Ltd.’s product portfolio, including Bone-Vio® and Bone-X, related to bone health targeting the human gastrointestinal microbiome.
- Entered into a binding letter of intent to acquire Pharmaceutical Laboratories CANA S.A., a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.
https://twitter.com/MoonMarket_/status/1599850735323136000
To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below



Recent News: Cosmos Health Provides a Summary Regarding Recent Share Activity and Reiterates its Belief and Commitment to the Financial Strength and the Growth and Profitability of the Company
On December 2 COSM provided a summary regarding recent share activity, including the participation of CEO, Greg Siokas on all capital raises. Management reiterates its belief in the financial strength of Cosmos Health, and its commitment to the growth and profitability of the Company.
In February and October of 2022 Cosmos successfully conducted two separate rounds of financings, with the combined proceeds of $13.5M. Furthermore, the Company has noted significant exercises of warrants in the month of November. As such, management now expects that by the end of Year End 2022, debt should decline by roughly 50% versus prior year levels.
Mr. Siokas has not sold any shares and has no plans to sell any of his shares.
Greg Siokas, Chief Executive Officer of Cosmos Health stated, “I am excited to see Cosmos emerge in to in a stronger financial position. We have had two successful capital raises in 2022, both of which I happily participated in for a combined amount of $3M. Since 2019, I have invested over $10.6M at an average price of $5.25 of my personal assets in Cosmos, as I have always believed in its growth and profitability prospects. My interests have always been and will continue to be aligned with those of shareholders, and I am constantly working to make sure shareholder value is realized. Given our new financial stability, I am hopeful about the future of Cosmos and our ability to rapidly grow as an international health and wellness company with multiple strong brands. I want to thank our shareholders and our team members who have helped us through this journey.”
For More on COSM Subscribe Right Now!
Currently trading at a $46 million market valuation COSM os is 83,797,481 the Company recently reported Q3 Revenues of $12 million down a bit from the same time last year due to a high variation in FX differences between EUR and GBP to USD. COSM was trading over $4 this time last year however OS has increased substantially since then. COSM is an exciting opportunity in small caps; the stock was shorted into oblivion and currently there are minimum 10 million shares short and was way oversold to pennies and it looked as if it would definitely get delisted by the Nasdaq however, led by able CEO Grigorios Siokas, Cosmos is fighting back. Mr. Siokas continues to buy more COSM at current price levels, putting his money where his mouth is as COSM rockets towards $1. As for the Nasdaq delisting COSM appealed it and has (until otherwise annouinced) until January 23 to get the bid over $1 We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.
Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.